Jacques F. Meis

List of Publications by Year
in descending order

550 papers	38,642 citations	3531 90 h-index	5120 166 g-index
557 all docs	557 docs citations	557 times ranked	20984 citing authors

#	Article	IF	Citations
1	Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus. Clinical Infectious Diseases, 2002, 34, 7-14.	5.8	2,255
2	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
3	Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clinical Infectious Diseases, 2017, 64, 134-140.	5.8	1,099
4	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
5	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clinical and Experimental Allergy, 2013, 43, 850-873.	2.9	666
6	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	9.1	586
7	Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clinical Microbiology and Infection, 2011, 17, 1859-1867.	6.0	566
8	ESCMIDâ€ and ECMMâ€¡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection, 2014, 20, 5-26.	6.0	547
9	First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrobial Resistance and Infection Control, 2016, 5, 35.	4.1	535
10	Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathogens, 2017, 13, e1006290.	4.7	501
11	Azole Resistance inAspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?. Clinical Infectious Diseases, 2016, 62, 362-368.	5.8	468
12	Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. Journal of Clinical Microbiology, 2015, 53, 1823-1830.	3.9	409
13	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clinical Microbiology and Infection, 2014, 20, 76-98.	6.0	400
14	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clinical Microbiology and Infection, 2014, 20, 27-46.	6.0	383
15	A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009â€“17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. Journal of Antimicrobial Chemotherapy, 2018, 73, 891-899.	3.0	380
16	First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. Journal of Infection, 2016, 73, 369-374.	3.3	340
17	New Clonal Strain ofCandida auris, Delhi, India. Emerging Infectious Diseases, 2013, 19, 1670-1673.	4.3	320
18	Fusarium: Molecular Diversity and Intrinsic Drug Resistance. PLoS Pathogens, 2016, 12, e1005464.	4.7	314

#	Article	IF	Citations
19	Multidrug-resistant endemic clonal strain of Candida auris in India. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 919-926.	2.9	303
20	Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health. PLoS Pathogens, 2013, 9, e1003633.	4.7	300
21	In vitro susceptibilities of zygomycetes to conventional and new antifungals. Journal of Antimicrobial Chemotherapy, 2003, 51, 45-52.	3.0	299
22	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. Journal of Clinical Microbiology, 2007, 45, 1735-1745.	3.9	269
23	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clinical Microbiology and Infection, 2014, 20, 47-75.	6.0	262
24	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	14.4	262
25	Potential Fifth Clade ofCandida auris,Iran, 2018. Emerging Infectious Diseases, 2019, 25, 1780-1781.	4.3	257
26	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	7.3	255
27	Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species. Antimicrobial Agents and Chemotherapy, 2012, 56, 2635-2642.	3.2	244
28	Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150460.	4.0	243
29	High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses, 2018, 61, 477-484.	4.0	237
30	An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses, 2018, 61, 498-505.	4.0	236
31	In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates. Antimicrobial Agents and Chemotherapy, 2003, 47, 106-117.	3.2	234
32	In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 62-68.	3.2	230
33	Use of a Novel Panel of Nine Short Tandem Repeats for Exact and High-Resolution Fingerprinting of Aspergillus fumigatus Isolates. Journal of Clinical Microbiology, 2005, 43, 4112-4120.	3.9	230
34	Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 5898-5906.	3.2	212
35	Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment. Journal of Infectious Diseases, 2017, 216, S436-S444.	4.0	199
36	Candida krusei , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology, 2008, 46, 515-521.	3.9	195

#	Article	IF	Citations
37	Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?. Antimicrobial Agents and Chemotherapy, 2013, 57, 5836-5842.	3.2	192
38	Clonal Expansion and Emergence of Environmental Multiple-Triazole-Resistant Aspergillus fumigatus Strains Carrying the TR34/L98H Mutations in the cyp51A Gene in India. PLoS ONE, 2012, 7, e52871.	2.5	180
39	COVID-19â€“Associated Pulmonary Aspergillosis, Marchâ€“August 2020. Emerging Infectious Diseases, 2021, 27, 1077-1086.	4.3	175
40	Allergic bronchopulmonary mycosis due to fungi other thanAspergillus: a global overview. Critical Reviews in Microbiology, 2014, 40, 30-48.	6.1	174
41	Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. Journal of Antimicrobial Chemotherapy, 2012, 67, 362-366.	3.0	173
42	Genomic Context of Azole Resistance Mutations in Aspergillus fumigatus Determined Using Whole-Genome Sequencing. MBio, 2015, 6, e00536.	4.1	171
43	Analysis of Growth Characteristics of Filamentous Fungi in Different Nutrient Media. Journal of Clinical Microbiology, 2001, 39, 478-484.	3.9	168
44	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The, 2021, 21, e246-e257.	9.1	167
45	Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature Medicine, 2000, 6, 1258-1263.	30.7	165
46	High Prevalence of Azole-Resistant Aspergillus fumigatus in Adults with Cystic Fibrosis Exposed to Itraconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 869-874.	3.2	164
47	Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. Journal of Antimicrobial Chemotherapy, 2015, 70, 1522-1526.	3.0	161
48	Candida guilliermondii , an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. Journal of Clinical Microbiology, 2006, 44, 3551-3556.	3.9	160
49	Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis. Antimicrobial Agents and Chemotherapy, 2003, 47, 3647-3650.	3.2	156
50	Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Diversity, 2014, 67, 1-10.	12.3	152
51	Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management. Journal of Fungi (Basel, Switzerland), 2019, 5, 55.	3.5	149
52	Nosocomial fungal infections: candidemia. Diagnostic Microbiology and Infectious Disease, 1999, 34, 213-220.	1.8	148
53	Colorimetric Assay for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 3402-3408.	3.9	148
54	Epidemiology and molecular mechanisms of antifungal resistance inÂCandida and Aspergillus. Mycoses, 2016, 59, 198-219.	4.0	142

#	Article	IF	Citations
55	ECMM/ISHAM recommendations for clinical management of COVIDâ€19 associated mucormycosis in lowâ€• and middleâ€•income countries. Mycoses, 2021, 64, 1028-1037.	4.0	137
56	Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales. Journal of Clinical Microbiology, 2012, 50, 66-75.	3.9	134
57	Autochthonous and DormantCryptococcus gattiiInfections in Europe. Emerging Infectious Diseases, 2012, 18, 1618-1624.	4.3	132
58	Molecular Epidemiology of Aspergillus fumigatus Isolates Recovered from Water, Air, and Patients Shows Two Clusters of Genetically Distinct Strains. Journal of Clinical Microbiology, 2003, 41, 4101-4106.	3.9	131
59	Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine. Antimicrobial Agents and Chemotherapy, 2012, 56, 3107-3113.	3.2	129
60	Primary structure and localization of a conserved immunogenicPlasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Molecular and Biochemical Parasitology, 1991, 49, 119-131.	1.1	128
61	Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clinical Microbiology and Infection, 2019, 25, 799-806.	6.0	128
62	Molecular Epidemiology of Aspergillus fumigatus Isolates Harboring the TR ₃₄ /L98H Azole Resistance Mechanism. Journal of Clinical Microbiology, 2012, 50, 2674-2680.	3.9	127
63	Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clinical Microbiology and Infection, 2016, 22, 277.e1-277.e9.	6.0	127
64	A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagnostic Microbiology and Infectious Disease, 2001, 40, 27-33.	1.8	126
65	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the Cryptococcus Genus. MSphere, 2017, 2, .	2.9	124
66	Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis. PLoS Pathogens, 2015, 11, e1004884.	4.7	123
67	In-host adaptation and acquired triazole resistance in Aspergillus fumigatus : a dilemma for clinical management. Lancet Infectious Diseases, The, 2016, 16, e251-e260.	9.1	123
68	Ancient Dispersal of the Human Fungal Pathogen Cryptococcus gattii from the Amazon Rainforest. PLoS ONE, 2013, 8, e71148.	2.5	122
69	Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. Journal of Antimicrobial Chemotherapy, 2014, 69, 2979-2983.	3.0	122
70	Candidemia in intensive care unit patients: Risk factors for mortality. Infection, 1997, 25, 8-11.	4.7	121
71	In Vitro Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental Cryptococcus gattii Isolates. Antimicrobial Agents and Chemotherapy, 2010, 54, 5139-5145.	3.2	121
72	Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 909-912.	2.9	120

#	Article	IF	Citations
73	Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiology, 2014, 9, 697-711.	2.0	118
74	Triazole resistance surveillance in Aspergillus fumigatus. Medical Mycology, 2018, 56, S83-S92.	0.7	114
75	European expert opinion on the management of invasive candidiasis in adults. Clinical Microbiology and Infection, 2011, 17, 1-12.	6.0	113
76	Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. Journal of Antimicrobial Chemotherapy, 2014, 69, 555-557.	3.0	113
77	International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2016, 60, 1079-1084.	3.2	113
78	RespiFinder: a New Multiparameter Test To Differentially Identify Fifteen Respiratory Viruses. Journal of Clinical Microbiology, 2008, 46, 1232-1240.	3.9	112
79	Phylogenomic Analysis of a 55.1-kb 19-Gene Dataset Resolves a MonophyleticFusariumthat Includes theFusarium solaniSpecies Complex. Phytopathology, 2021, 111, 1064-1079.	2.2	107
80	Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae. Antimicrobial Agents and Chemotherapy, 2015, 59, 6581-6587.	3.2	106
81	In Vitro Interaction of Terbinafine with Itraconazole against Clinical Isolates of Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2000, 44, 470-472.	3.2	105
82	A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence. MBio, 2017, 8, .	4.1	104
83	Induction of SLPI (ALP/HUSI-I) in Epidermal Keratinocytes. Journal of Investigative Dermatology, 1998, 111, 996-1002.	0.7	99
84	Assessingin vitrocombinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Medical Mycology, 2005, 43, 133-152.	0.7	99
85	Environmental study of azoleâ€resistant <scp>A</scp>spergillus fumigatus with TR₃₄/L98H mutations in the cyp51A gene in <scp>I</scp>ran. Mycoses, 2013, 56, 659-663.	4.0	98
86	Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses, 2018, 61, 377-382.	4.0	98
87	Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B, Posaconazole, and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales. Antimicrobial Agents and Chemotherapy, 2015, 59, 1745-1750.	3.2	97
88	Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis : a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology, 2008, 46, 842-849.	3.9	96
89	Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and Voriconazole. Antimicrobial Agents and Chemotherapy, 2014, 58, 2006-2012.	3.2	96
90	Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006â€“2008). Clinical Microbiology and Infection, 2015, 21, 87.e1-87.e10.	6.0	96

#	Article	IF	Citations
91	Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia. Scientific Reports, 2017, 7, 45631.	3.3	96
92	Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. Journal of Hospital Infection, 2001, 47, 143-148.	2.9	95
93	Cystatin M/E Expression is Restricted to Differentiated Epidermal Keratinocytes and Sweat Glands: a New Skin-Specific Proteinase Inhibitor that is a Target for Cross-Linking by Transglutaminase. Journal of Investigative Dermatology, 2001, 116, 693-701.	0.7	94
94	A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile. Fungal Genetics and Biology, 2019, 133, 103266.	2.1	93
95	High prevalence of azole resistance inAspergillus fumigatusisolates from high-risk patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 2894-2898.	3.0	92
96	Schizophyllum commune as an emerging fungal pathogen: a review and report of two cases. Mycoses, 2013, 56, 1-10.	4.0	91
97	Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Frontiers in Microbiology, 2015, 06, 428.	3.5	89
98	Multiâ€triazoleâ€resistant Aspergillus fumigatus infections in Australia. Mycoses, 2015, 58, 350-355.	4.0	89
99	Global molecular epidemiology and genetic diversity of Fusarium , a significant emerging group of human opportunists from 1958 to 2015. Emerging Microbes and Infections, 2016, 5, 1-11.	6.5	89
100	Nationwide Survey of In Vitro Activities of Itraconazole and Voriconazole against Clinical Aspergillus fumigatus Isolates Cultured between 1945 and 1998. Journal of Clinical Microbiology, 2002, 40, 2648-2650.	3.9	88
101	Candida rugosa , an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. Journal of Clinical Microbiology, 2006, 44, 3578-3582.	3.9	88
102	Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report. Journal of Fungi (Basel, Switzerland), 2020, 6, 79.	3.5	88
103	Identification and typing of the emerging pathogen Candida auris by matrixâ€assisted laser desorption ionisation time of flight mass spectrometry. Mycoses, 2016, 59, 535-538.	4.0	86
104	Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infectious Diseases, 2018, 18, 24.	2.9	86
105	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clinical Microbiology and Infection, 2014, 20, 1-4.	6.0	85
106	The worldâ€™s ten most feared fungi. Fungal Diversity, 2018, 93, 161-194.	12.3	85
107	Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water. Epidemiology and Infection, 1998, 120, 251-256.	2.1	84
108	Current antifungal treatment of fusariosis. International Journal of Antimicrobial Agents, 2018, 51, 326-332.	2.5	83

#	Article	IF	Citations
109	Geographically Structured Populations of Cryptococcus neoformans Variety grubii in Asia Correlate with HIV Status and Show a Clonal Population Structure. PLoS ONE, 2013, 8, e72222.	2.5	83
110	Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for Aspergillus spp. for the CLSI M38-A2 Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2013, 57, 3823-3828.	3.2	82
111	Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. Journal of Antimicrobial Chemotherapy, 2015, 70, 1068-71.	3.0	81
112	Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally acquired?. Journal of Global Antimicrobial Resistance, 2015, 3, 69-74.	2.2	81
113	Serial monitoring ofAspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection, 1997, 25, 86-89.	4.7	80
114	Current Management of Fungal Infections. Drugs, 2001, 61, 13-25.	10.9	80
115	In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents. Antimicrobial Agents and Chemotherapy, 2002, 46, 2708-2711.	3.2	78
116	Frequency and Geographic Distribution of CARD9 Mutations in Patients With Severe Fungal Infections. Frontiers in Microbiology, 2018, 9, 2434.	3.5	78
117	Genotypic Characterization of Sequential Candida albicans Isolates from Fluconazole-Treated Neutropenic Patients. Journal of Infectious Diseases, 1994, 169, 1062-1070.	4.0	77
118	Identification of Four Distinct Genotypes of Candida dubliniensis and Detection of Microevolution In Vitro and In Vivo. Journal of Clinical Microbiology, 2002, 40, 556-574.	3.9	77
119	Functional and morphological monocyte abnormalities in a patient with malakoplakia. American Journal of Medicine, 1998, 105, 74-77.	1.5	76
120	Passive Surveillance for Azole-ResistantAspergillus fumigatus, United States, 2011â€“2013. Emerging Infectious Diseases, 2014, 20, 1498-1503.	4.3	76
121	Recognizing filamentous basidiomycetes as agents of human disease: A review. Medical Mycology, 2014, 52, 782-797.	0.7	76
122	Taxonomy of the Trichophyton mentagrophytes/T. interdigitale Species Complex Harboring the Highly Virulent, Multiresistant Genotype T. indotineae. Mycopathologia, 2021, 186, 315-326.	3.1	76
123	In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	75
124	Candida auris otomycosis in Iran and review of recent literature. Mycoses, 2019, 62, 101-105.	4.0	75
125	Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nature Microbiology, 2020, 5, 1516-1531.	13.3	75
126	In Vitro Interaction of Flucytosine Combined with Amphotericin B or Fluconazole against Thirty-Five Yeast Isolates Determined by both the Fractional Inhibitory Concentration Index and the Response Surface Approach. Antimicrobial Agents and Chemotherapy, 2002, 46, 2982-2989.	3.2	74

#	Article	IF	Citations
127	Changing epidemiology of an emerging infection: zygomycosis. Clinical Microbiology and Infection, 2009, 15, 10-14.	6.0	73
128	Cladophialophora psammophila, a novel species of Chaetothyriales with a potential use in the bioremediation of volatile aromatic hydrocarbons. Fungal Biology, 2011, 115, 1019-1029.	2.5	73
129	Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	72
130	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.. Journal of Antimicrobial Chemotherapy, 1998, 42, 389-392.	3.0	71
131	Comparison of Spectrophotometric and Visual Readings of NCCLS Method and Evaluation of a Colorimetric Method Based on Reduction of a Soluble Tetrazolium Salt, 2,3-Bis {2-Methoxy-4-Nitro-5-[(Sulfenylamino) Carbonyl]-2H- Tetrazolium-Hydroxide}, for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 4256-4263.	3.9	71
132	Black yeast-like fungi associated with Lethargic Crab Disease (LCD) in the mangrove-land crab, Ucides cordatus (Ocypodidae). Veterinary Microbiology, 2012, 158, 109-122.	1.9	71
133	Global Population Genetic Analysis of Aspergillus fumigatus. MSphere, 2017, 2, .	2.9	71
134	Nonrandom Distribution of Azole Resistance across the Global Population of Aspergillus fumigatus. MBio, 2019, 10, .	4.1	71
135	Environmental prevalence ofCryptococcus neoformansandCryptococcus gattiiin India: An update. Critical Reviews in Microbiology, 2012, 38, 1-16.	6.1	70
136	Taxonomy and epidemiology of <I>Mucor irregularis</I> , agent of chronic cutaneous mucormycosis. Persoonia: Molecular Phylogeny and Evolution of Fungi, 2013, 30, 48-56.	4.4	69
137	Interlaboratory Comparison of Sample Preparation Methods, Database Expansions, and Cutoff Values for Identification of Yeasts by Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry Using a Yeast Test Panel. Journal of Clinical Microbiology, 2014, 52, 3023-3029.	3.9	69
138	Candida auris: a global fungal public health threat. Lancet Infectious Diseases, The, 2018, 18, 1298-1299.	9.1	69
139	Erysipelas-like skin lesions associated withCampylobacter jejuni septicemia in patients with hypogammaglobulinemia. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 842-847.	2.9	67
140	Apophysomyces elegans : Epidemiology, Amplified Fragment Length Polymorphism Typing, and In Vitro Antifungal Susceptibility Pattern. Journal of Clinical Microbiology, 2010, 48, 4580-4585.	3.9	67
141	Malaria parasitesâ€”discovery of the early liver form. Nature, 1983, 302, 424-426.	27.8	66
142	Molecular Identification and Susceptibility ofTrichosporonSpecies Isolated from Clinical Specimens in Qatar: Isolation ofTrichosporon dohaenseTaj-Aldeen, Meis & Boekhout sp. nov. Journal of Clinical Microbiology, 2009, 47, 1791-1799.	3.9	66
143	The first cases of Candida auris candidaemia in Oman. Mycoses, 2017, 60, 569-575.	4.0	66
144	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	3.5	66

#	Article	IF	Citations
145	In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba. Antimicrobial Agents and Chemotherapy, 2008, 52, 1580-1582.	3.2	65
146	Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogenAspergillus fumigatus. Molecular Ecology, 2012, 21, 57-70.	3.9	65
147	Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice. Journal of Clinical Microbiology, 2015, 53, 1056-1062.	3.9	65
148	Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. Journal of Antimicrobial Chemotherapy, 2010, 65, 901-905.	3.0	64
149	Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait. Environmental Research, 2014, 133, 20-26.	7.5	64
150	In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses, 2015, 58, 303-307.	4.0	64
151	Plasmodium falciparum ookinetes migrate intercellularly throughAnopheles stephensi midgut epithelium. Parasitology Research, 1989, 76, 13-19.	1.6	63
152	A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagnostic Microbiology and Infectious Disease, 2000, 36, 215-223.	1.8	63
153	Intercountry Transfer of Triazole-Resistant Aspergillus fumigatus on Plant Bulbs. Clinical Infectious Diseases, 2017, 65, 147-149.	5.8	63
154	Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice 1. Medical Mycology, 1999, 37, 419-426.	0.7	62
155	Microsatellite based typing of Aspergillus fumigatus: Strengths, pitfalls and solutions. Journal of Microbiological Methods, 2007, 69, 268-272.	1.6	62
156	Draft Genome Sequence of a Fluconazole-Resistant Candida auris Strain from a Candidemia Patient in India. Genome Announcements, 2015, 3, .	0.8	62
157	Candida auris. Current Opinion in Infectious Diseases, 2018, 31, 334-340.	3.1	62
158	Temperate Climate Niche forCryptococcus gattiiin Northern Europe. Emerging Infectious Diseases, 2012, 18, 172-174.	4.3	62
159	Ultrastructural studies on the interaction of Plasmodium falciparum ookinetes with the midgut epithelium of Anopheles stephensi mosquitoes. Zeitschrift FÃ¼r Parasitenkunde (Berlin, Germany), 1987, 73, 500-506.	0.8	61
160	Comparison of Two Highly Discriminatory Molecular Fingerprinting Assays for Analysis of Multiple Aspergillus fumigatus Isolates from Patients with Invasive Aspergillosis. Journal of Clinical Microbiology, 2007, 45, 1415-1419.	3.9	61
161	Susceptibility and Diversity in the Therapy-Refractory Genus Scedosporium. Antimicrobial Agents and Chemotherapy, 2014, 58, 5877-5885.	3.2	61
162	First Description of Azole-Resistant Aspergillus fumigatus Due to TR ₄₆ /Y121F/T289A Mutation in France. Antimicrobial Agents and Chemotherapy, 2015, 59, 4331-4335.	3.2	61

#	Article	IF	Citations
163	Emergence of clonal fluconazole-resistant Candida parapsilosis clinical isolates in a multicentre laboratory-based surveillance study in India. Journal of Antimicrobial Chemotherapy, 2019, 74, 1260-1268.	3.0	61
164	No to Neocosmospora : Phylogenomic and Practical Reasons for Continued Inclusion of the Fusarium solani Species Complex in the Genus Fusarium. MSphere, 2020, 5, .	2.9	61
165	Prevention of Intra-abdominal Abscesses and Adhesions Using a Hyaluronic Acid Solution in a Rat Peritonitis Model. Archives of Surgery, 1999, 134, 997.	2.2	60
166	Clinical Significance and Molecular Characterization of Nonsporulating Molds Isolated from the Respiratory Tracts of Bronchopulmonary Mycosis Patients with Special Reference to Basidiomycetes. Journal of Clinical Microbiology, 2013, 51, 3331-3337.	3.9	60
167	Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 2855-2866.	3.2	60
168	EQUAL Candida Score: An <scp>ECMM</scp> score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses, 2018, 61, 326-330.	4.0	60
169	Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. Aids, 2000, 14, 2787-2788.	2.2	60
170	A novel protein antigen of the malaria parasite Plasmodium falciparum, located on the surface of gametes and sporozoites. Molecular and Biochemical Parasitology, 1991, 45, 193-204.	1.1	59
171	Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2002, 40, 2876-2885.	3.9	59
172	Uncommon opportunistic yeast bloodstream infections from Qatar. Medical Mycology, 2014, 52, 552-556.	0.7	59
173	Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern. Infection, 2014, 42, 393-404.	4.7	58
174	Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex Using the CLSI M27-A3 Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2015, 59, 666-668.	3.2	58
175	A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. Antimicrobial Agents and Chemotherapy, 2015, 59, 6615-6619.	3.2	58
176	In Vitro Activities of Eight Antifungal Drugs against 55 Clinical Isolates of Fonsecaea spp. Antimicrobial Agents and Chemotherapy, 2010, 54, 1636-1638.	3.2	57
177	Species boundaries and nomenclature of Rhizopus arrhizus (syn. R. oryzae). Mycoses, 2014, 57, 108-127.	4.0	56
178	Development of Candida auris Short Tandem Repeat Typing and Its Application to a Global Collection of Isolates. MBio, 2020, 11, .	4.1	56
179	Use of Amplified Fragment Length Polymorphism To Identify 42 Cladophialophora Strains Related to Cerebral Phaeohyphomycosis with In Vitro Antifungal Susceptibility. Journal of Clinical Microbiology, 2010, 48, 2350-2356.	3.9	55
180	Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Medical Mycology, 2010, 48, 696-703.	0.7	55

#	Article	IF	Citations
181	Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. Journal of Antimicrobial Chemotherapy, 2015, 70, 412-415.	3.0	55
182	Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerging Microbes and Infections, 2016, 5, 1-12.	6.5	55
183	Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients â€“ A Dutch, multicentre study. Journal of Cystic Fibrosis, 2019, 18, 221-226.	0.7	55
184	Infections caused by Gemella morbillorum. Lancet, The, 1993, 342, 560.	13.7	54
185	Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection, 1994, 22, 81-85.	4.7	54
186	Identification by Molecular Methods and Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry and Antifungal Susceptibility Profiles of Clinically Significant Rare Aspergillus Species in a Referral Chest Hospital in Delhi, India. Journal of Clinical Microbiology, 2016, 54, 2354-2364.	3.9	54
187	Clade-specific chromosomal rearrangements and loss of subtelomeric adhesins in Candida auris. Genetics, 2021, 218, .	2.9	54
188	Comparison of Fractional Inhibitory Concentration Index with Response Surface Modeling for Characterization of In Vitro Interaction of Antifungals against Itraconazole-Susceptible and -Resistant Aspergillus fumigatus Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 702-707.	3.2	53
189	Extensive Genetic Diversity within the Dutch Clinical Cryptococcus neoformans Population. Journal of Clinical Microbiology, 2012, 50, 1918-1926.	3.9	53
190	Molecular Epidemiology and In-Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Isolates in Delhi, India: Evidence of Genetic Diversity by Amplified Fragment Length Polymorphism and Microsatellite Typing. PLoS ONE, 2015, 10, e0118997.	2.5	53
191	In vitrocombinations of natamycin with voriconazole, itraconazole and micafungin against clinicalFusariumstrains causing keratitis: TableÂ1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 953-955.	3.0	53
192	Interlaboratory reproducibility of a microsatellite-based typing assay for Aspergillus fumigatus through the use of allelic ladders: proof of concept. Clinical Microbiology and Infection, 2009, 15, 180-187.	6.0	52
193	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	4.0	52
194	Utility of a microsatellite assay for identifying clonally related outbreak isolates of Aspergillus fumigatus. Journal of Microbiological Methods, 2008, 73, 252-256.	1.6	51
195	Molecular Epidemiology of Aspergillus fumigatus: an In-Depth Genotypic Analysis of Isolates Involved in an Outbreak of Invasive Aspergillosis. Journal of Clinical Microbiology, 2011, 49, 3498-3503.	3.9	51
196	Microsatellite Typing of Clinical and Environmental Cryptococcus neoformans var. grubii Isolates from Cuba Shows Multiple Genetic Lineages. PLoS ONE, 2010, 5, e9124.	2.5	51
197	Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis. Antimicrobial Agents and Chemotherapy, 2002, 46, 1953-1959.	3.2	50
198	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999â€“2015. Clinical Infectious Diseases, 2017, 65, 216-225.	5.8	50

#	Article	IF	Citations
199	Procalcitonin Does Not Discriminate Infection from Inflammation after Allogeneic Bone Marrow Transplantation. Vaccine Journal, 2000, 7, 889-892.	2.6	49
200	Microsatellite Genotyping Clarified Conspicuous Accumulation of Candida parapsilosis at a Cardiothoracic Surgery Intensive Care Unit. Journal of Clinical Microbiology, 2012, 50, 3422-3426.	3.9	49
201	Azole resistance surveillance inAspergillus fumigatus: beneficial or biased?. Journal of Antimicrobial Chemotherapy, 2016, 71, 2079-2082.	3.0	49
202	Antifungal Susceptibility Testing of Fusarium: A Practical Approach. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 To	3.5	49
203	Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil. Frontiers in Microbiology, 2019, 10, 737.	3.5	49
204	Killing of Candida auris by <scp>UV</scp>â€C: Importance of exposure time and distance. Mycoses, 2019, 62, 408-412.	4.0	49
205	Invasive Infections Due to Trichosporon : Species Distribution, Genotyping, and Antifungal Susceptibilities from a Multicenter Study in China. Journal of Clinical Microbiology, 2019, 57, .	3.9	49
206	Antifungal Susceptibility and Mutations in the Squalene Epoxidase Gene in Dermatophytes of the Trichophyton mentagrophytes Species Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0005621.	3.2	49
207	Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India. Mycoses, 2014, 57, 97-107.	4.0	48
208	Photodynamic fungicidal efficacy of hypericin and dimethyl methylene blue against azoleâ€resistant Candida albicans strains. Mycoses, 2014, 57, 35-42.	4.0	48
209	Home Environment as a Source of Life-Threatening Azole-ResistantAspergillus fumigatusin Immunocompromised Patients: Table 1.. Clinical Infectious Diseases, 2017, 64, 76-78.	5.8	48
210	Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS. Frontiers in Cellular and Infection Microbiology, 2019, 9, 20.	3.9	48
211	COVIDâ€19â€“associated pulmonary aspergillosis: a prospective singleâ€center dual case series. Mycoses, 2021, 64, 457-464.	4.0	48
212	Prevalence and Clonal Distribution of Azole-Resistant Candida parapsilosis Isolates Causing Bloodstream Infections in a Large Italian Hospital. Frontiers in Cellular and Infection Microbiology, 2020, 10, 232.	3.9	48
213	Emergence of azole resistant Aspergillus fumigatus and One Health: time to implement environmental stewardship. Environmental Microbiology, 2018, 20, 1299-1301.	3.8	47
214	In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses, 2011, 54, e583-9.	4.0	46
215	Filamentous Fungi in Respiratory Infections. What Lies Beyond Aspergillosis and Mucormycosis?. PLoS Pathogens, 2016, 12, e1005491.	4.7	46
216	Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses, 2016, 59, 576-584.	4.0	46

#	Article	IF	Citations
217	Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013â€“2018. Emerging Infectious Diseases, 2020, 26, 1447-1455.	4.3	46
218	Transformation of sporozoites of Plasmodium berghei into exoerythrocytic forms in the liver of its mammalian host. Cell and Tissue Research, 1985, 241, 353-360.	2.9	45
219	Non-CS pre-erythrocytic protective antigens. Immunology Letters, 1990, 25, 71-76.	2.5	45
220	In Vitro Antifungal Activity of Isavuconazole against Madurella mycetomatis. Antimicrobial Agents and Chemotherapy, 2012, 56, 6054-6056.	3.2	45
221	Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis. Diagnostic Microbiology and Infectious Disease, 2012, 73, 57-64.	1.8	45
222	Severe Disseminated Phaeohyphomycosis in an Immunocompetent Patient Caused by Veronaea botryosa. Mycopathologia, 2013, 175, 497-503.	3.1	44
223	Simple, Low-Cost Detection of Candida parapsilosis Complex Isolates and Molecular Fingerprinting of Candida orthopsilosis Strains in Kuwait by ITS Region Sequencing and Amplified Fragment Length Polymorphism Analysis. PLoS ONE, 2015, 10, e0142880.	2.5	44
224	ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	44
225	The clinical spectrum ofExophiala jeanselmei, with a case report andin vitroantifungal susceptibility of the species. Medical Mycology, 2010, 48, 318-327.	0.7	43
226	Taxonomy and Antifungal Susceptibility of Clinically Important Rasamsonia Species. Journal of Clinical Microbiology, 2013, 51, 22-30.	3.9	43
227	Routine identification of Nocardia species by MALDI-TOF mass spectrometry. Diagnostic Microbiology and Infectious Disease, 2017, 87, 7-10.	1.8	43
228	In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagnostic Microbiology and Infectious Disease, 2011, 71, 370-377.	1.8	42
229	Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight Candida Species and the CLSI M27-A3 Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2014, 58, 916-922.	3.2	42
230	Resistance of Asian Cryptococcus neoformans Serotype A Is Confined to Few Microsatellite Genotypes. PLoS ONE, 2012, 7, e32868.	2.5	42
231	Delay in Administering the First Dose of Antibiotics in Patients Admitted to Hospital with Serious Infections. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 681-684.	2.9	41
232	In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2002, 46, 3323-3326.	3.2	41
233	Burkholderia fungorumSepticemia. Emerging Infectious Diseases, 2005, 11, 1115-1117.	4.3	41
234	Molecular typing of Aspergillus species. Mycoses, 2008, 51, 463-476.	4.0	41

#	Article	IF	Citations
235	Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 110-114.	0.7	41
236	Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist. Medical Mycology, 2011, 49, 819-824.	0.7	41
237	Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser. Journal of Medical Microbiology, 2013, 62, 1763-1767.	1.8	41
238	Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species. Antimicrobial Agents and Chemotherapy, 2015, 59, 7882-7887.	3.2	41
239	A scanning electron microscopic study of the sporogonic development of Plasmodium falciparum in Anopheles stephensi. Acta Tropica, 1992, 50, 227-236.	2.0	40
240	Candida nivariensis Isolated from an Indonesian Human Immunodeficiency Virus-Infected Patient Suffering from Oropharyngeal Candidiasis. Journal of Clinical Microbiology, 2008, 46, 388-391.	3.9	40
241	DNA barcoding, MALDI-TOF, and AFLP data support Fusarium ficicrescens as a distinct species within the Fusarium fujikuroi species complex. Fungal Biology, 2016, 120, 265-278.	2.5	40
242	Low sensitivity of implant sonication when screening for infection in revision surgery. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 294-299.	3.3	40
243	Perspectives on misidentification of Trichophyton interdigitale/Trichophyton mentagrophytes using internal transcribed spacer region sequencing: Urgent need to update the sequence database. Mycoses, 2019, 62, 11-15.	4.0	40
244	Axillary Digital Thermometers uplifted a multidrugâ€susceptible Candidaauris outbreak among COVIDâ€19 patients in Brazil. Mycoses, 2021, 64, 1062-1072.	4.0	40
245	Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clinical Microbiology and Infection, 2000, 6, 336-337.	6.0	39
246	Microbiological diagnosis of invasive fungal infections in transplant recipients. Transplant Infectious Disease, 2000, 2, 80-87.	1.7	39
247	Fonsecaea multimorphosa sp. nov, a new species of Chaetothyriales isolated from a feline cerebral abscess. Fungal Biology, 2011, 115, 1066-1076.	2.5	39
248	Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains. Antimicrobial Agents and Chemotherapy, 2016, 60, 6916-6919.	3.2	39
249	Rapid Susceptibility Testing and Microcolony Analysis of Candida spp. Cultured and Imaged on Porous Aluminum Oxide. PLoS ONE, 2012, 7, e33818.	2.5	39
250	Microbial profiling does not differentiate between childhood recurrent acute otitis media and chronic otitis media with effusion. International Journal of Pediatric Otorhinolaryngology, 2013, 77, 488-493.	1.0	38
251	Treatment of prosthetic joint infections due toPropionibacterium. Monthly Notices of the Royal Astronomical Society: Letters, 2016, 87, 60-66.	3.3	38
252	Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates. Journal of Fungi (Basel, Switzerland), 2018, 4, 103.	3.5	38

#	Article	IF	Citations
253	Subcutaneous phaeohyphomycotic cyst caused byPyrenochaeta romeroi. Medical Mycology, 2010, 48, 763-768.	0.7	37
254	Clinical Significance of Filamentous Basidiomycetes Illustrated by Isolates of the Novel Opportunist Ceriporia lacerata from the Human Respiratory Tract. Journal of Clinical Microbiology, 2013, 51, 585-590.	3.9	37
255	The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species. Medical Mycology, 2010, 48, 1-10.	0.7	37
256	Global prevalence and subgroup analyses of coronavirus disease (<scp>COVID</scp>â€19) associated Candida auris infections (<scp>CACa</scp>): A systematic review and metaâ€analysis. Mycoses, 2022, 65, 683-703.	4.0	37
257	An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of Hematology, 1995, 70, 83-87.	1.8	36
258	Utility of CSP typing to sub-type clinical Aspergillus fumigatus isolates and proposal for a new CSP type nomenclature. Journal of Microbiological Methods, 2009, 77, 292-296.	1.6	36
259	First Autochthonous Case of Rhinocladiella mackenziei Cerebral Abscess Outside the Middle East. Journal of Clinical Microbiology, 2010, 48, 646-649.	3.9	36
260	Keratitis by Fusarium temperatum, a novel opportunist. BMC Infectious Diseases, 2014, 14, 588.	2.9	36
261	The post-vaccine microevolution of invasive Streptococcus pneumoniae. Scientific Reports, 2015, 5, 14952.	3.3	36
262	Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses, 2016, 59, 101-107.	4.0	36
263	Antifungal Susceptibility and Phylogeny of Opportunistic Members of the GenusFusariumCausing Human Keratomycosis in South India. Medical Mycology, 2016, 54, 287-294.	0.7	36
264	Cryptococcus gattii Induces a Cytokine Pattern That Is Distinct from Other Cryptococcal Species. PLoS ONE, 2013, 8, e55579.	2.5	36
265	Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses, 2011, 54, 12-21.	4.0	35
266	Molecular Characterization and In Vitro Antifungal Susceptibility Profile of Schizophyllum commune, an Emerging Basidiomycete in Bronchopulmonary Mycoses. Antimicrobial Agents and Chemotherapy, 2013, 57, 2845-2848.	3.2	35
267	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe, The, 2022, 3, e464-e470.	7.3	35
268	In Vitro Interactions between Amphotericin B, Itraconazole, and Flucytosine against 21 Clinical Aspergillus Isolates Determined by Two Drug Interaction Models. Antimicrobial Agents and Chemotherapy, 2004, 48, 2007-2013.	3.2	34
269	Ongoing Challenges with Healthcare-Associated Candida auris Outbreaks in Oman. Journal of Fungi (Basel, Switzerland), 2019, 5, 101.	3.5	34
270	Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 Deficiency. Journal of Clinical Immunology, 2019, 39, 462-469.	3.8	34

#	Article	IF	Citations
271	Fungicide-driven alterations in azole-resistantAspergillus fumigatusare related to vegetable crops in Colombia, South America. Mycologia, 2019, 111, 217-224.	1.9	34
272	Epidemiological features of nosocomial candidaemia in neonates, infants and children: A multicentre study in Iran. Mycoses, 2020, 63, 382-394.	4.0	34
273	Phagocytosis and Killing of Candida albicans by Human Neutrophils After Exposure to Structurally Different Lipid Emulsions. Journal of Parenteral and Enteral Nutrition, 2001, 25, 9-13.	2.6	33
274	Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates. Mycoses, 2014, 57, 380-387.	4.0	33
275	Molecular and Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry-Based Characterization of Clinically Significant Melanized Fungi in India. Journal of Clinical Microbiology, 2017, 55, 1090-1103.	3.9	33
276	Molecular Epidemiology of Candida Auris Outbreak in a Major Secondary-Care Hospital in Kuwait. Journal of Fungi (Basel, Switzerland), 2020, 6, 307.	3.5	33
277	Microsatellite typing and susceptibilities of serial Cryptococcus neoformansisolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infectious Diseases, 2010, 10, 289.	2.9	32
278	Isothermal microcalorimetry: a novel method for real-time determination of antifungal susceptibility of Aspergillus species. Clinical Microbiology and Infection, 2012, 18, E241-E245.	6.0	32
279	Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	32
280	In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014â€‰â€“â€‰2015. BMC Microbiology, 2015, 15, 121.	3.3	31
281	Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe. Journal of Infection, 2016, 72, 745-752.	3.3	31
282	Effects of the Natural Peptide Crotamine from a South American Rattlesnake on Candida auris, an Emergent Multidrug Antifungal Resistant Human Pathogen. Biomolecules, 2019, 9, 205.	4.0	31
283	Electron microscopic studies on the interaction of rat Kupffer cells andPlasmodium berghei sporozoites. Zeitschrift FÃ¼r Parasitenkunde (Berlin, Germany), 1985, 71, 473-483.	0.8	30
284	Fine structure of the malaria parasite Plasmodium falciparum in human hepatocytes in vitro. Cell and Tissue Research, 1986, 244, 345-50.	2.9	30
285	Plasmodium falciparum: Studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. Experimental Parasitology, 1990, 70, 1-11.	1.2	30
286	Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: Case report and review of the literature. Infection, 1997, 25, 109-111.	4.7	30
287	In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	30
288	Ecoepidemiology of Cryptococcus gattii in Developing Countries. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (S	3.5	30

#	Article	IF	Citations
289	Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris. International Journal of Antimicrobial Agents, 2020, 56, 106049.	2.5	30
290	High-Frequency Direct Detection of Triazole Resistance in Aspergillus fumigatus from Patients with Chronic Pulmonary Fungal Diseases in India. Journal of Fungi (Basel, Switzerland), 2020, 6, 67.	3.5	30
291	Cellulitis as First Clinical Presentation of Disseminated Cryptococcosis in Renal Transplant Recipients. Scandinavian Journal of Infectious Diseases, 1994, 26, 623-626.	1.5	29
292	A case of imported paracoccidioidomycosis: an awkward infection in the Netherlands. Medical Mycology, 2006, 44, 13-18.	0.7	29
293	A rare case of allergic bronchopulmonary mycosis caused byAlternaria alternata. Medical Mycology, 2012, 50, 890-896.	0.7	29
294	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Journal of Antimicrobial Chemotherapy, 2018, 73, 134-142.	3.0	29
295	In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex. Mycoses, 2018, 61, 134-142.	4.0	29
296	Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2018, 4, 129.	3.5	29
297	First azoleâ€resistant Aspergillus fumigatus isolates with the environmental TR₄₆/Y121F/T289A mutation in Iran. Mycoses, 2020, 63, 430-436.	4.0	29
298	Colonisation and Transmission Dynamics of Candida auris among Chronic Respiratory Diseases Patients Hospitalised in a Chest Hospital, Delhi, India: A Comparative Analysis of Whole Genome Sequencing and Microsatellite Typing. Journal of Fungi (Basel, Switzerland), 2021, 7, 81.	3.5	29
299	High Resolution Genotyping of Clinical Aspergillus flavus Isolates from India Using Microsatellites. PLoS ONE, 2011, 6, e16086.	2.5	29
300	Oral terbinafine for treatment of pulmonaryPseudallescheria boydii infection refractory to itraconazole therapy. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 26-28.	2.9	28
301	In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs. Mycoses, 2000, 43, 309-312.	4.0	28
302	Effect of pH on the In Vitro Activities of Amphotericin B, Itraconazole, and Flucytosine against Aspergillus Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 3147-3150.	3.2	28
303	Internal validation of <scp>GPS</scp>^{â„¢}<scp>MONODOSE</scp> CanAur dtecâ€<scp>qPCR</scp> kit following the <scp>UNE</scp>/<scp>EN ISO</scp>/<scp>IEC</scp> 17025:2005 for detection of the emerging yeast Candida auris. Mycoses, 2018, 61, 877-884.	4.0	28
304	Antifungal Activity of a Medical-Grade Honey Formulation against Candida auris. Journal of Fungi (Basel, Switzerland), 2021, 7, 50.	3.5	28
305	Cryptococcus neoformans population diversity and clinical outcomes of HIV-associated cryptococcal meningitis patients in Zimbabwe. Journal of Medical Microbiology, 2016, 65, 1281-1288.	1.8	28
306	Phylogenetic relationships of five species ofAspergillusand related taxa as deduced by comparison of sequences of small subunit ribosomal RNA. Medical Mycology, 1995, 33, 185-190.	0.7	27

#	Article	IF	Citations
307	Progress in fighting systemic fungal infections in haematological neoplasia. Supportive Care in Cancer, 1997, 6, 31-38.	2.2	27
308	Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	27
309	Fluconazole in the management of fungal urinary tract infections. Infection, 1994, 22, 247-251.	4.7	26
310	In Vitro Activities at pH 5.0 and pH 7.0 and In Vivo Efficacy of Flucytosine against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2008, 52, 4483-4485.	3.2	26
311	In vitro activities of antifungal drugs against Rhinocladiella mackenziei, an agent of fatal brain infection. Journal of Antimicrobial Chemotherapy, 2010, 65, 175-177.	3.0	26
312	Severe prosthetic joint infection in an immunocompetent male patient due to a therapy refractory Pseudallescheria apiosperma. Mycoses, 2011, 54, 22-27.	4.0	26
313	Environmental isolation and characterisation of Cryptococcus species from living trees in Havana city, Cuba. Mycoses, 2012, 55, e138-44.	4.0	26
314	In Vitro Antifungal Susceptibility of Cladophialophora carrionii, an Agent of Human Chromoblastomycosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1974-1977.	3.2	26
315	Roussoella percutanea, a novel opportunistic pathogen causing subcutaneous mycoses. Medical Mycology, 2014, 52, 689-698.	0.7	26
316	Fusarium species causing eumycetoma: Report of two cases and comprehensive review of the literature. Mycoses, 2017, 60, 204-212.	4.0	26
317	Outbreak of Fusarium oxysporum infections in children with cancer: an experience with 7 episodes of catheter-related fungemia. Antimicrobial Resistance and Infection Control, 2017, 6, 93.	4.1	26
318	Molecular identification tools for sibling species ofScedosporiumandPseudallescheria. Medical Mycology, 2012, 50, 497-508.	0.7	25
319	First neonatal case of fungaemia due to <scp>P</scp>seudozyma aphidis and a global literature review. Mycoses, 2014, 57, 64-68.	4.0	25
320	Molecular Diagnostics of Arthroconidial Yeasts, Frequent Pulmonary Opportunists. Journal of Clinical Microbiology, 2018, 56, .	3.9	25
321	Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1704-1712.	3.0	25
322	Epidemiology of Aspergillus species causing keratitis in Mexico. Mycoses, 2019, 62, 144-151.	4.0	25
323	Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiaryâ€care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins. Mycoses, 2022, 65, 331-343.	4.0	25
324	No Evidence for a Relation Between Borrelia burgdorferi Infection and Old Lesions of Localized Scleroderma (Morphea). Archives of Dermatology, 1993, 129, 386.	1.4	24

#	Article	IF	Citations
325	Method for Measuring Postantifungal Effect in Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2002, 46, 1960-1965.	3.2	24
326	Hyaluronic acid-based agents do not affect anastomotic strength in the rat colon, in either the presence or absence of bacterial peritonitis. British Journal of Surgery, 2002, 87, 1222-1228.	0.3	24
327	Antifungal activity of human polymorphonuclear and mononuclear phagocytes against nonâ€‹fumigatus Aspergillus species. Mycoses, 2003, 46, 77-83.	4.0	24
328	In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates of Alternaria species. Journal of Antimicrobial Chemotherapy, 2009, 63, 1295-1297.	3.0	24
329	Subcutaneous phaeohyphomycosis caused by Exophiala equina, with susceptibility to eight antifungal drugs. Journal of Medical Microbiology, 2013, 62, 797-800.	1.8	24
330	Phage-Derived Protein Induces Increased Platelet Activation and Is Associated with Mortality in Patients with Invasive Pneumococcal Disease. MBio, 2017, 8, .	4.1	24
331	In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species. Mycopathologia, 2019, 184, 607-613.	3.1	24
332	Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline? . Infection and Drug Resistance, 2019, Volume 12, 3727-3737.	2.7	24
333	A Cluster of Candida auris Blood Stream Infections in a Tertiary Care Hospital in Oman from 2016 to 2019. Antibiotics, 2020, 9, 638.	3.7	24
334	Multiple brain abscesses and bacteremia in a child due toFusobacterium necrophorum. Infection, 1993, 21, 174-176.	4.7	23
335	In Vitro Activities of Pentamidine, Pyrimethamine, Trimethoprim, and Sulfonamides against Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2002, 46, 2029-2031.	3.2	23
336	Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium and zygomycetes. Mycoses, 2007, 50, 270-276.	4.0	23
337	Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India. Diagnostic Microbiology and Infectious Disease, 2013, 76, 46-50.	1.8	23
338	Voriconazole-Resistant Penicillium oxalicum: An Emerging Pathogen in Immunocompromised Hosts. Open Forum Infectious Diseases, 2014, 1, ofu029.	0.9	23
339	Different colonization patterns of Aspergillus terreus in patients with cystic fibrosis. Clinical Microbiology and Infection, 2014, 20, 327-333.	6.0	23
340	Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia. Journal of Antimicrobial Chemotherapy, 2014, 69, 2258-2264.	3.0	23
341	Detection and serotyping of pneumococci in community acquired pneumonia patients without culture using blood and urine samples. BMC Infectious Diseases, 2015, 15, 56.	2.9	23
342	Geographically predominant genotypes of Aspergillus terreus species complex in Austria: s microsatellite typing study. Clinical Microbiology and Infection, 2016, 22, 270-276.	6.0	23

#	Article	IF	Citations
343	Burden of serious fungal infections in the Netherlands. Mycoses, 2020, 63, 625-631.	4.0	23
344	In vitroactivity of the novel antifungal olorofim against dermatophytes and opportunistic moulds includingPenicilliumandTalaromycesspecies. Journal of Antimicrobial Chemotherapy, 2021, 76, 1229-1233.	3.0	23
345	High-resolution fingerprinting of Candida parapsilosis isolates suggests persistence and transmission of infections among neonatal intensive care unit patients in Kuwait. Scientific Reports, 2019, 9, 1340.	3.3	23
346	Pneumopericardium complicating invasive pulmonary aspergillosis: Case report and review. Infection, 1994, 22, 102-105.	4.7	22
347	Epidemiological survey of an outbreak of multiresistantSerratia marcescens by PCR-fingerprinting. Infection, 1995, 23, 267-271.	4.7	22
348	Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Current Medical Research and Opinion, 2005, 21, 1535-1546.	1.9	22
349	Retrotransposon insertion-site context (RISC) typing: A novel typing method for Aspergillus fumigatus and a convenient PCR alternative to restriction fragment length polymorphism analysis. Journal of Microbiological Methods, 2007, 70, 528-534.	1.6	22
350	Meningitis caused by Filobasidium uniguttulatum: case report and overview of the literature. Mycoses, 2012, 55, 105-109.	4.0	22
351	Veronaea botryosa: Molecular Identification with Amplified Fragment Length Polymorphism (AFLP) and In vitro Antifungal Susceptibility. Mycopathologia, 2013, 175, 505-513.	3.1	22
352	First environmental isolation of Cryptococcus gattii, genotype AFLP5, from India and a global review. Mycoses, 2013, 56, 222-228.	4.0	22
353	In Vitro Activities of Eight Antifungal Drugs against 104 Environmental and Clinical Isolates of Aureobasidium pullulans. Antimicrobial Agents and Chemotherapy, 2014, 58, 5629-5631.	3.2	22
354	Multilocus sequence typing of Candida africana from patients with vulvovaginal candidiasis in New Delhi, India. Mycoses, 2014, 57, 544-552.	4.0	22
355	Antifungal Susceptibility of Emerging Dimorphic Pathogens in the Family Ajellomycetaceae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	22
356	Evaluation of DermaGenius^{Â®} resistance realâ€time polymerase chain reaction for rapid detection of terbinafineâ€resistant Trichophyton species. Mycoses, 2021, 64, 721-726.	4.0	22
357	The biology of tissue forms and other asexual stages in mammalian plasmodia. Experientia, 1984, 40, 1317-1329.	1.2	21
358	Bordetella bronchiseptica bronchitis in an immunosuppressed patient. European Journal of Clinical Microbiology and Infectious Diseases, 1990, 9, 366-367.	2.9	21
359	Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient. Transplant Infectious Disease, 2000, 2, 96-98.	1.7	21
360	Prophylaxis and treatment of fungal infections associated with haematological malignancies. International Journal of Antimicrobial Agents, 2000, 15, 159-168.	2.5	21

#	Article	IF	Citations
361	Quality Control Limits for Fluconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue. Journal of Clinical Microbiology, 2003, 41, 3410-3412.	3.9	21
362	Identification and Typing of Isolates of Cyphellophora and Relatives by Use of Amplified Fragment Length Polymorphism and Rolling Circle Amplification. Journal of Clinical Microbiology, 2013, 51, 931-937.	3.9	21
363	Global Spread of Human Chromoblastomycosis Is Driven by Recombinant Cladophialophora carrionii and Predominantly Clonal Fonsecaea Species. PLoS Neglected Tropical Diseases, 2015, 9, e0004004.	3.0	21
364	Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
365	Environmental distribution of Cryptococcus species and some other yeastâ€like fungi in India. Mycoses, 2018, 61, 305-313.	4.0	21
366	The Contribution of Genetic Variation of Streptococcus pneumoniae to the Clinical Manifestation of Invasive Pneumococcal Disease. Clinical Infectious Diseases, 2019, 68, 61-69.	5.8	21
367	An unusual case of gastrointestinal basidiobolomycosis mimicking colon cancer; literature and review. Journal De Mycologie Medicale, 2019, 29, 75-79.	1.5	21
368	Evaluation of Microsatellite Typing, ITS Sequencing, AFLP Fingerprinting, MALDI-TOF MS, and Fourier-Transform Infrared Spectroscopy Analysis of Candida auris. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 457 Td	3.5	21
369	Multiple subcutaneous cysts due toExophiala spiniferain an immunocompetent patient. Medical Mycology, 2012, 50, 207-213.	0.7	20
370	In Vitro Activities of Nine Antifungal Drugs against 81 Phialophora and Cyphellophora Isolates. Antimicrobial Agents and Chemotherapy, 2012, 56, 6044-6047.	3.2	20
371	Chromoblastomycosis due to Fonsecaea pedrosoi and F. monophora in Cuba. Mycopathologia, 2013, 175, 439-444.	3.1	20
372	Simple, Low-Cost Molecular Assays for TR34/L98H Mutations in the cyp51A Gene for Rapid Detection of Triazole-Resistant Aspergillus fumigatus Isolates. Journal of Clinical Microbiology, 2014, 52, 2223-2227.	3.9	20
373	Fatal Disseminated Infection with Fusarium petroliphilum. Mycopathologia, 2015, 179, 119-124.	3.1	20
374	Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study. Medical Mycology, 2018, 56, 406-415.	0.7	20
375	Epidemiology and aetiologies of cryptococcal meningitis in Africa, 1950â€“2017: protocol for a systematic review. BMJ Open, 2018, 8, e020654.	1.9	20
376	Candida blankii: an emerging yeast in an outbreak of fungaemia in neonates in Delhi, India. Clinical Microbiology and Infection, 2020, 26, 648.e5-648.e8.	6.0	20
377	Antifungal activity of nitroxoline against Candida auris isolates. Clinical Microbiology and Infection, 2021, 27, 1697.e7-1697.e10.	6.0	20
378	South Asian (Clade I) Candida auris meningitis in a paediatric patient in Iran with a review of the literature. Mycoses, 2022, 65, 134-139.	4.0	20

#	Article	IF	Citations
379	Rapidly fatal Q-fever pneumonia in a patient with chronic granulomatous disease. Infection, 1992, 20, 287-289.	4.7	19
380	Endophthalmitis as presenting symptom of group G streptococcal endocarditis. Infection, 1994, 22, 56-57.	4.7	19
381	The Plasmodium falciparum knob-associated PfEMP3 antigen is also expressed at pre-erythrocytic stages and induces antibodies which inhibit sporozoite invasion. Molecular and Biochemical Parasitology, 2001, 112, 253-261.	1.1	19
382	Relationship between In Vitro Activities of Amphotericin B and Flucytosine and pH for Clinical Yeast and Mold Isolates. Antimicrobial Agents and Chemotherapy, 2005, 49, 3341-3346.	3.2	19
383	Genetic Relatedness between Pneumococcal Populations Originating from the Nasopharynx, Adenoid, and Tympanic Cavity of Children with Otitis Media. Journal of Clinical Microbiology, 2005, 43, 3140-3144.	3.9	19
384	Isothermal microcalorimetry for antifungal susceptibility testing of Mucorales, Fusarium spp., and Scedosporium spp.. Diagnostic Microbiology and Infectious Disease, 2012, 73, 330-337.	1.8	19
385	Whole Genome-Based Amplified Fragment Length Polymorphism Analysis Reveals Genetic Diversity in Candida africana. Frontiers in Microbiology, 2017, 8, 556.	3.5	19
386	ECMM CandiRegâ€”A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
387	One year prospective survey of azole resistance in Aspergillus fumigatus at a French cystic fibrosis reference centre: prevalence and mechanisms of resistance. Journal of Antimicrobial Chemotherapy, 2019, 74, 1884-1889.	3.0	19
388	Fasâ€FasL Interactions Modulate Host Defense against SystemicCandida albicansInfection. Journal of Infectious Diseases, 1999, 180, 1648-1655.	4.0	18
389	Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. Transplant Infectious Disease, 2002, 4, 64-65.	1.7	18
390	Proximal subungual onychomycosis caused byFusarium falciformesuccessfully cured with posaconazole. British Journal of Dermatology, 2015, 173, 253-255.	1.5	18
391	Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
392	Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
393	The First Two Cases of CandidaÂauris in The Netherlands. Journal of Fungi (Basel, Switzerland), 2019, 5, 91.	3.5	18
394	A Chronic Autochthonous Fifth Clade Case of Candida auris Otomycosis in Iran. Mycopathologia, 2022, 187, 121-127.	3.1	18
395	Collateral consequences of agricultural fungicides on pathogenic yeasts: A One Health perspective to tackle azole resistance. Mycoses, 2022, 65, 303-311.	4.0	18
396	Clostridium cadaveris bacteraemia: Two cases and review. Scandinavian Journal of Infectious Diseases, 2006, 38, 59-62.	1.5	17

#	Article	IF	Citations
397	In Vitro Antifungal Susceptibility Profile and Correlation of Mycelial and Yeast Forms of Molecularly Characterized Histoplasma capsulatum Strains from India. Antimicrobial Agents and Chemotherapy, 2014, 58, 5613-5616.	3.2	17
398	Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei in Persian Gulf region: A case and review. Mycoses, 2018, 61, 261-265.	4.0	17
399	Evaluation One Year after DAIR Treatment in 91 Suspected Early Prosthetic Joint Infections in Primary Knee and Hip Arthroplasty. Journal of Bone and Joint Infection, 2019, 4, 238-244.	1.5	17
400	cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
401	PYOSALPINX CAUSED BY STREPTOCOCCUS PNEVMONIAE IN A YOUNG GIRL. Pediatric Infectious Disease Journal, 1993, 12, 539.	2.0	16
402	Cryptococcal meningitis due to Cryptococcus neoformans genotype <scp>AFLP</scp>1/<scp>VNI</scp> in Iran: a review of the literature. Mycoses, 2015, 58, 689-693.	4.0	16
403	Debridement, antibiotics and implant retention in early postoperative infection with Enterococcus sp.. Clinical Microbiology and Infection, 2015, 21, e41-e42.	6.0	16
404	Differential Kinetics of Aspergillus nidulans and Aspergillus fumigatus Phagocytosis. Journal of Innate Immunity, 2018, 10, 145-160.	3.8	16
405	Molecular epidemiology of environmental Cryptococcus species isolates based on amplified fragment length polymorphism. Journal De Mycologie Medicale, 2018, 28, 599-605.	1.5	16
406	Clonal Expansion of Environmental Triazole Resistant Aspergillus fumigatus in Iran. Journal of Fungi (Basel, Switzerland), 2020, 6, 199.	3.5	16
407	Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: A nationwide study. Medical Mycology, 2020, 58, 859-866.	0.7	16
408	Histochemical observations on the exoerythrocytic malaria parasite Plasmodium berghei in rat liver. Histochemistry, 1984, 81, 417-425.	1.9	15
409	Fine structure of exoerythrocytic forms in cultured primary rat hepatocytes. Cell Biology International Reports, 1984, 8, 755-765.	0.6	15
410	Polymerase chain reaction as a diagnostic tool for invasive aspergillosis: evaluation in bronchoalveolar lavage fluid from low risk patients. Serodiagnosis and Immunotherapy in Infectious Disease, 1994, 6, 203-208.	0.2	15
411	Fatal Cerebral Phaeohyphomycosis in an Immunocompetent Individual Due to Thielavia subthermophila. Journal of Clinical Microbiology, 2011, 49, 2336-2341.	3.9	15
412	Reactivation of a Cryptococcus gattii infection in a cheetah (Acinonyx jubatus) held in the National Zoo, Havana, Cuba. Mycoses, 2011, 54, e889-e892.	4.0	15
413	Fatal Cryptococcus gattii genotype AFLP5 infection in an immunocompetent Cuban patient. Medical Mycology Case Reports, 2013, 2, 48-51.	1.3	15
414	Cryptococcus and Cryptococcosis in Cuba. A minireview. Mycoses, 2014, 57, 707-717.	4.0	15

#	Article	IF	Citations
415	The Concept of Ecthyma Gangrenosum Illustrated by a Fusarium oxysporum Infection in an Immunocompetent Individual. Mycopathologia, 2016, 181, 759-763.	3.1	15
416	Intra- and Interlaboratory Agreement in Assessing theIn VitroActivity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods. Antimicrobial Agents and Chemotherapy, 2016, 60, 6173-6178.	3.2	15
417	Fusarium metavorans sp. nov.: The frequent opportunist â€˜FSSC6â€™. Medical Mycology, 2018, 56, S144-S152.	0.7	15
418	Postâ€influenzal triazoleâ€resistant aspergillosis following allogeneic stem cell transplantation. Mycoses, 2018, 61, 570-575.	4.0	15
419	Molecular Characterization and Antifungal Susceptibility Testing of Sequentially Obtained Clinical Cryptococcus deneoformans and Cryptococcus neoformans Isolates from Ljubljana, Slovenia. Mycopathologia, 2018, 183, 371-380.	3.1	15
420	In vitro characterization, ADME analysis, and histological and toxicological evaluation of BM1, a macrocyclic amidinourea active against azole-resistant Candida strains. International Journal of Antimicrobial Agents, 2020, 55, 105865.	2.5	15
421	Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. Journal of Medical Microbiology, 2018, 67, 560-569.	1.8	15
422	First Human Case of Pulmonary Fungal Ball Due to a Perenniporia Species (a Basidiomycete). Journal of Clinical Microbiology, 2012, 50, 3786-3791.	3.9	14
423	Molecular Identification and Susceptibility Pattern of ClinicalNocardiaSpecies: Emergence ofNocardia crassostreaeas an Agent of Invasive Nocardiosis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, e33-e38.	1.9	14
424	Validation of a novel real-time PCR for detecting Rasamsonia argillacea species complex in respiratory secretions from cystic fibrosis patients. New Microbes and New Infections, 2014, 2, 72-78.	1.6	14
425	Direct molecular versus culture-based assessment of Gram-positive cocci in biopsies of patients with major abscesses and diabetic foot infections. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1885-1892.	2.9	14
426	Comparative genotyping and phenotyping of Aspergillus fumigatus isolates from humans, dogs and the environment. BMC Microbiology, 2018, 18, 118.	3.3	14
427	Microsatellite Stability in STR Analysis Aspergillus fumigatus Depends on Number of Repeat Units. Frontiers in Cellular and Infection Microbiology, 2019, 9, 82.	3.9	14
428	Quality Control Limits for Voriconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue. Journal of Clinical Microbiology, 2004, 42, 1716-1718.	3.9	13
429	Airway persistence by the emerging multiâ€azoleâ€resistant Rasamsonia argillacea complex in cystic fibrosis. Mycoses, 2018, 61, 665-673.	4.0	13
430	INVASIVE ASPERGILLOSIS IN TWO PATIENTS WITH PEARSON SYNDROME. Pediatric Infectious Disease Journal, 1999, 18, 739-741.	2.0	13
431	Detection of different developmental stages of malaria parasites by non-radioactive DNAin situ hybridization. The Histochemical Journal, 1991, 23, 109-115.	0.6	12
432	FatalClostridium perfringens meningitis associated with insertion of a ventriculo-peritoneal shunt. European Journal of Clinical Microbiology and Infectious Diseases, 1993, 12, 720-721.	2.9	12

#	Article	IF	Citations
433	CROSS-INFECTION WITH PSEUDOMONAS AERUGINOSA IN A NEONATAL INTENSIVE CARE UNIT CHARACTERIZED BY POLYMERASE CHAIN REACTION FINGERPRINTING. Pediatric Infectious Disease Journal, 1993, 12, 1027-1028.	2.0	12
434	Septic shock caused by group G Î²-haemolytic streptococci as presenting symptom of acute myeloid leukaemia. Netherlands Journal of Medicine, 1995, 46, 153-155.	0.5	12
435	Interactions of human phagocytes with mouldsFusariumspp. andVerticilliumnigrescenspossessing different pathogenicity1. Medical Mycology, 2003, 41, 503-509.	0.7	12
436	Avidity of Antibodies against Infecting Pneumococcal Serotypes Increases with Age and Severity of Disease. Vaccine Journal, 2014, 21, 904-907.	3.1	12
437	Diagnostic value of serum pneumococcal DNA load during invasive pneumococcal infections. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1119-1124.	2.9	12
438	Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 265-271.	2.9	12
439	Molecular characterization of Cryptococcus gattii genotype AFLP6/VGII isolated from woody debris of divi-divi (Caesalpinia coriaria), Bonaire, Dutch Caribbean. Revista Iberoamericana De Micologia, 2014, 31, 193-196.	0.9	12
440	Genotyping of clinical and environmental Aspergillus flavus isolates from Iran using microsatellites. Mycoses, 2016, 59, 220-225.	4.0	12
441	Are the TR ₄₆ /Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?. Antimicrobial Agents and Chemotherapy, 2016, 60, 3259-3260.	3.2	12
442	In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe. Diagnostic Microbiology and Infectious Disease, 2016, 86, 289-292.	1.8	12
443	Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus. Journal of Antimicrobial Chemotherapy, 2019, 74, 2950-2958.	3.0	12
444	Nontypeable Haemophilus influenzae Invasive Blood Isolates Are Mainly Phosphorylcholine Negative and Show Decreased Complement-Mediated Killing That Is Associated with Lower Binding of IgM and CRP in Comparison to Colonizing Isolates from the Oropharynx. Infection and Immunity, 2019, 87, .	2.2	12
445	Genotypic diversity in clinical and environmental isolates ofCryptococcus neoformansfrom India using multilocus microsatellite and multilocus sequence typing. Mycoses, 2020, 63, 284-293.	4.0	12
446	Comparison of Two Commercially Available qPCR Kits for the Detection of Candida auris. Journal of Fungi (Basel, Switzerland), 2021, 7, 154.	3.5	12
447	Infection of cryopreserved adult human hepatocytes with sporozoites. Cell Biology International Reports, 1985, 9, 976.	0.6	11
448	Localization of circumsporozoite protein in the sporogonic stages ofPlasmodium vivax. Parasitology Research, 1992, 78, 165-167.	1.6	11
449	Imported Talaromycosis in Oman in Advanced HIV: A Diagnostic Challenge Outside the Endemic Areas. Mycopathologia, 2017, 182, 739-745.	3.1	11
450	Adjunctive interferon-Î³ immunotherapy in a pediatric case of Aspergillus terreus infection. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1915-1922.	2.9	11

#	Article	IF	Citations
451	External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris. Journal of Fungi (Basel, Switzerland), 2019, 5, 94.	3.5	11
452	A pseudoâ€outbreak of Rhinocladiella similis in a bronchoscopy unit of a tertiary care teaching hospital in London, United Kingdom. Mycoses, 2021, 64, 394-404.	4.0	11
453	Environmental Detection of SARS-CoV-2 Virus RNA in Health Facilities in Brazil and a Systematic Review on Contamination Sources. International Journal of Environmental Research and Public Health, 2021, 18, 3824.	2.6	11
454	An adult case of oral infection with Kingella kingae. International Journal of Oral and Maxillofacial Surgery, 2004, 33, 105-107.	1.5	10
455	Effects of 7-valent pneumococcal conjugate 1 vaccine on the severity of adult 2 bacteremic pneumococcal pneumonia. Vaccine, 2014, 32, 3989-3994.	3.8	10
456	Debridement, antibiotics and implant retention in early postoperative infection with Pseudomonas aeruginosa. Journal of Infection, 2015, 70, 307-309.	3.3	10
457	In Vitro Activities of Eight Antifungal Drugs against a Global Collection of Genotyped Exserohilum Isolates. Antimicrobial Agents and Chemotherapy, 2015, 59, 6642-6645.	3.2	10
458	Production of the Invasive Aspergillosis Biomarker Bis(methylthio)gliotoxin Within the Genus Aspergillus: In Vitro and in Vivo Metabolite Quantification and Genomic Analysis. Frontiers in Microbiology, 2018, 9, 1246.	3.5	10
459	Emergence of Candida auris in intensive care units in Algeria. Mycoses, 2022, 65, 753-759.	4.0	10
460	Analysis of an outbreak of puerperal fever due to group A streptococci by random amplified polymorphic DNA fingerprinting. , 1997, 5, 232-236.		9
461	LOCAL EXPRESSION OF CYTOKINE mRNA IN SPLEEN AND PEYER'S PATCHES OF RATS IS INVOLVED IN RESISTANCE AGAINST INFECTION WITHYERSINIA ENTEROCOLITICA. Cytokine, 1998, 10, 206-212.	3.2	9
462	Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis. Medical Mycology, 2009, 47, 802-807.	0.7	9
463	USA300 Methicillin-resistant Staphylococcus aureus in Cuba. Antimicrobial Resistance and Infection Control, 2012, 1, 2.	4.1	9
464	Invasive Mycosis Due to Species of Blastobotrys in Immunocompromised Patients with Reduced Susceptibility to Antifungals. Journal of Clinical Microbiology, 2014, 52, 4094-4099.	3.9	9
465	In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium. Antimicrobial Agents and Chemotherapy, 2015, 59, 7818-7822.	3.2	9
466	Comparison of biotyping methods as alternative identification tools to molecular typing of pathogenic <scp>C</scp>ryptococcus species in subâ€Saharan Africa. Mycoses, 2016, 59, 151-156.	4.0	9
467	Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients. Microbial Pathogenesis, 2018, 115, 353-357.	2.9	9
468	Mycotic Keratitis Caused by Fusarium solani sensu stricto (FSSC5): A Case Series. Mycopathologia, 2018, 183, 835-840.	3.1	9

#	Article	IF	Citations
469	Extensive tinea capitis and corporis in a child caused by TrichophytonÂverrucosum. Journal De Mycologie Medicale, 2019, 29, 62-66.	1.5	9
470	Activities of nine antifungal agents against Candida auris biofilms. Mycoses, 2021, 64, 381-384.	4.0	9
471	Development of a Multiplex PCR Short Tandem Repeat Typing Scheme for Candida krusei. Journal of Clinical Microbiology, 2022, 60, JCM0203221.	3.9	9
472	Persistent Yersinia enterocolitica infection in three rat strains. Microbial Pathogenesis, 1995, 19, 57-63.	2.9	8
473	Sepsis puerperalis caused by a genotypically proven cat-derived Pasteurella multocida strain. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1998, 76, 71-73.	1.1	8
474	Discovery of a sexual cycle inTalaromyces amestolkiae. Mycologia, 2016, 108, 70-79.	1.9	8
475	In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions. Diagnostic Microbiology and Infectious Disease, 2018, 91, 266-268.	1.8	8
476	Use of cell surface protein typing for genotyping of azoleâ€resistant and â€susceptible Aspergillus fumigatus isolates in Iran. Mycoses, 2018, 61, 143-147.	4.0	8
477	Thermogenic Characterization and Antifungal Susceptibility of Candida auris by Microcalorimetry. Journal of Fungi (Basel, Switzerland), 2019, 5, 103.	3.5	8
478	European confederation of medical mycology expert consultâ€"An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	4.0	8
479	Diagnostic Allele-Specific PCR for the Identification of Candida auris Clades. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overl	3.5	8
480	Moulds and man. Journal of Antimicrobial Chemotherapy, 2009, 63, i21-i22.	3.0	7
481	Microcalorimetry Assay for Rapid Detection of Voriconazole Resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 5704-5706.	3.2	7
482	Bipolaris oryzae, a novel fungal opportunist causing keratitis. Diagnostic Microbiology and Infectious Disease, 2016, 85, 61-65.	1.8	7
483	Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
484	Differential In Vitro Cytokine Induction by the Species of Cryptococcus gattii Complex. Infection and Immunity, 2018, 86, .	2.2	7
485	Endophthalmitis caused by Purpureocillium lilacinum. Journal of Microbiology, Immunology and Infection, 2019, 52, 170-171.	3.1	7
486	A novel diagnosis scoring model to predict invasive pulmonary aspergillosis in the intensive care unit. Journal of King Abdulaziz University, Islamic Economics, 2019, 40, 140-146.	1.1	7

#	Article	IF	Citations
487	A simple and low cost tetra-primer ARMS-PCR method for detection triazole-resistant Aspergillus fumigatus. Molecular Biology Reports, 2019, 46, 4537-4543.	2.3	7
488	In vitro activity of nine antifungal agents against a global collection of Hortaea werneckii isolates, the agent of tinea nigra. International Journal of Antimicrobial Agents, 2019, 54, 95-98.	2.5	7
489	Candida auris in an Intensive Care Setting. New England Journal of Medicine, 2019, 380, 890-891.	27.0	7
490	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. Journal of Fungi (Basel, Switzerland), 2020, 6, 274.	3.5	7
491	Outbreak of Dirkmeia churashimaensis Fungemia in a Neonatal Intensive Care Unit, India. Emerging Infectious Diseases, 2020, 26, 764-768.	4.3	7
492	MALDIâ€TOF MS characterisation, genetic diversity and antifungal susceptibility of Trichosporon species from Iranian clinical samples. Mycoses, 2021, 64, 918-925.	4.0	7
493	Basidiobolus omanensis sp. nov. Causing Angioinvasive Abdominal Basidiobolomycosis. Journal of Fungi (Basel, Switzerland), 2021, 7, 653.	3.5	7
494	Prevention of invasive aspergillosis in AIDS by sulfamethoxazole. Aids, 2001, 15, 1067-1068.	2.2	7
495	Severe Disseminated Phaeohyphomycosis in a Patient with Inherited CARD9 Deficiency. Archives of Clinical Infectious Diseases, 2018, 13, .	0.2	7
496	Fatal Intrauterine Infection Associated with Mycoplasma hominis. Clinical Infectious Diseases, 1992, 15, 753-754.	5.8	6
497	Interactions of Yersinia enterocolitica with polarized human intestinal Caco-2 cells. Medical Microbiology and Immunology, 1995, 184, 123-127.	4.8	6
498	Resistance of Aspergillus fumigatus to Itraconazole. Scandinavian Journal of Infectious Diseases, 1998, 30, 642-642.	1.5	6
499	Fusarium ramigenum, a novel human opportunist in a patient with common variable immunodeficiency and cellular immune defects: case report. BMC Infectious Diseases, 2016, 16, 79.	2.9	6
500	Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates. Mycopathologia, 2020, 185, 357-365.	3.1	6
501	Are We Ready for Nosocomial Candida auris Infections? Rapid Identification and Antifungal Resistance Detection Using MALDI-TOF Mass Spectrometry May Be the Answer. Frontiers in Cellular and Infection Microbiology, 2021, 11, 645049.	3.9	6
502	Two Candida auris Cases in Germany with No Recent Contact to Foreign Healthcareâ€"Epidemiological and Microbiological Investigations. Journal of Fungi (Basel, Switzerland), 2021, 7, 380.	3.5	6
503	Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant Candida auris. Current Medical Mycology, 2019, 5, 26-30.	0.8	6
504	Microsatellite Genotyping of Candida parapsilosis Clinical Isolates. Current Medical Mycology, 2017, 3, 15-20.	0.8	6

#	Article	IF	Citations
505	Donor-Derived Transmission of Cryptococcus gattii sensu lato in Kidney Transplant Recipients. Emerging Infectious Diseases, 2020, 26, 1329-1331.	4.3	6
506	The demonstration ofPlasmodium berghei sporozoites in rat hepatocytes one hour after inoculation. Zeitschrift FÃ¼r Parasitenkunde (Berlin, Germany), 1982, 67, 345-348.	0.8	5
507	Intranuclear localization of sporozoites. Cell Biology International Reports, 1984, 8, 1016.	0.6	5
508	Swelling of hand and forearm caused by Mycobacterium bovis. Netherlands Journal of Medicine, 1999, 54, 70-72.	0.5	5
509	Pericarditis as complication of appendicitis. Annals of Thoracic Surgery, 2004, 78, 1086-1088.	1.3	5
510	Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
511	Genotyping of Aspergillus fumigatus in Formalin-Fixed Paraffin-Embedded Tissues and Serum Samples From Patients With Invasive Aspergillosis. Frontiers in Cellular and Infection Microbiology, 2018, 8, 377.	3.9	5
512	Cutibacterium acnes infections in revision surgery for persistent shoulder complaints: a retrospective cohort study. Archives of Orthopaedic and Trauma Surgery, 2021, 141, 197-205.	2.4	5
513	Disseminated Rhinocladiella mackenziei infection in a kidney transplant recipient: A case report and literature review. Journal De Mycologie Medicale, 2021, 31, 101196.	1.5	5
514	A novel quantitative PCR assay for the detection of Streptococcus pneumoniae using the competence regulator gene target comX. Journal of Medical Microbiology, 2016, 65, 129-136.	1.8	5
515	Candida aurisâ€"â€œTen Years Afterâ€• Journal of Fungi (Basel, Switzerland), 2020, 6, 2.	3.5	4
516	International Society for Human and Animal Mycology (ISHAM)â€"New Initiatives. Journal of Fungi (Basel, Switzerland), 2020, 6, 97.	3.5	4
517	Molecular typing and antifungal susceptibility study of Aspergillus spp. in intensive care unit (ICU) patients in Indonesia. Journal of Infection in Developing Countries, 2021, 15, 1014-1020.	1.2	4
518	Non-traumatic keratitis due to Colletotrichum truncatum. JMM Case Reports, 2016, 3, e005047.	1.3	4
519	Analysis of an Outbreak of Puerperal Fever Due to Group A Streptococci by Random Amplified Polymorphic DNA Fingerprinting. Infectious Diseases in Obstetrics and Gynecology, 1997, 5, 232-236.	1.5	4
520	Two-step polymerase chain reaction assay for detection of Yersinia species in general and of pathogenic Yersinia enterocolitica strains specifically. International Journal of Infectious Diseases, 1997, 1, 206-211.	3.3	3
521	Pharmacological agents in development for invasive aspergillosis. Expert Opinion on Emerging Drugs, 2002, 7, 33-45.	2.4	3
522	Reply to â€œImplications of High Antifungal Susceptibility on Schizophyllum commune-Associated Allergy in Clinical Practiceâ€• Antimicrobial Agents and Chemotherapy, 2013, 57, 5784-5785.	3.2	3

#	Article	IF	Citations
523	Bacteroides fragilis in biopsies of patients with major abscesses and diabetic foot infections: direct molecular versus culture-based detection. Diagnostic Microbiology and Infectious Disease, 2016, 85, 263-265.	1.8	3
524	Neonatal Cutaneous Invasive Aspergillosis Accompanied by Hemophagocytic Lymphohistocytosis. Pediatric Infectious Disease Journal, 2017, 36, 423-425.	2.0	3
525	Does Online Search Behavior Coincide with Candida auris Cases? An Exploratory Study. Journal of Fungi (Basel, Switzerland), 2019, 5, 44.	3.5	3
526	Genetic and Phenotypic Characterization of in-Host Developed Azole-Resistant Aspergillus flavus Isolates. Journal of Fungi (Basel, Switzerland), 2021, 7, 164.	3.5	3
527	In vitro activities of 8 antifungal drugs against 126 clinical and environmental Exophiala isolates. Mycoses, 2021, 64, 1328-1333.	4.0	3
528	Cryptococcus gattii genotype AFLP6/VGII meningoencephalitis in an immunocompetent Filipino male in Kuwait: activation of a dormant infection. JMM Case Reports, 2015, 2, .	1.3	3
529	Occurrence of Cryptococcus neoformans and other yeast-like fungi in environmental sources in Bonaire (Dutch Caribbean). Germs, 2020, 10, 195-200.	1.3	3
530	In vitro activity of 23 antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates. Mycoses, 0, , .	4.0	3
531	Cefpirome: Epidemiological Survey in Intensive Care Units and Hematological Units in the Netherlands. Diagnostic Microbiology and Infectious Disease, 1998, 31, 489-491.	1.8	2
532	Hip and knee arthroplasty: quo vadis?. Antimicrobial Resistance and Infection Control, 2015, 4, 19.	4.1	2
533	Brazil is so far free from Candida auris. Are we missing something?. Brazilian Journal of Infectious Diseases, 2019, 23, 149-150.	0.6	2
534	In vitro synergy of echinocandins with triazoles against fluconazole-resistant Candida parapsilosis complex isolates. Journal of Global Antimicrobial Resistance, 2020, 21, 331-334.	2.2	2
535	Ruling out underlying infection in 200 presumed aseptic knee and hip revision arthroplasties using a multiplex PCR system. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1283-1290.	2.9	2
536	Multi-locus sequence typing reveals genotypic similarity in Nigerian Cryptococcus neoformans AFLP1/VNI of environmental and clinical origin. Journal of Medical Microbiology, 2021, 70, .	1.8	2
537	OUP accepted manuscript. Medical Mycology, 2022, , .	0.7	2
538	Comparison of a few systems for the determination of saprobic and trophic degree on the basis of plankton data. Hydrobiologia, 1980, 70, 251-256.	2.0	1
539	Fulminant Neonatal Sepsis due to Haemophilus influenzae. Scandinavian Journal of Infectious Diseases, 1991, 23, 649-652.	1.5	1
540	COLONIZATION OF THE FEMALE GENITAL TRACT WITH HAEMOPHILUS INFLUENZAE. Pediatric Infectious Disease Journal, 1994, 13, 758.	2.0	1

#	Article	IF	Citations
541	Hand hygiene and health-care-associated infections. Lancet Infectious Diseases, The, 2007, 7, 304-305.	9.1	1
542	Antifungal resistance in clinically significant fungi. Fungal Genetics and Biology, 2020, 139, 103369.	2.1	1
543	In vitro activity of eight antifungal drugs against Chaetomiaceae. Medical Mycology, 2021, 60, .	0.7	1
544	CHRONIC POLYARTHRLTIS DUE TO PSEUDOMONAS AERUGINOSA. Rheumatology, 1993, 32, 1021-1022.	1.9	0
545	Prevalence of antibodies to Histoplasma capsulatum among dutch speleologists. Journal of Infection, 1998, 37, 200-201.	3.3	0
546	Reply to Letter to the Editor of J.H. van Loenhout-Rooyackers [published in the September issue of The Netherlands Journal of Medicine (1999;55:163)]. Netherlands Journal of Medicine, 1999, 55, 249.	0.5	0
547	New Clonal Strain ofCandida auris, Delhi, India. Emerging Infectious Diseases, 2013, 19, .	4.3	0
548	Invasive pulmonary aspergillosis in immunocompetent patients acquired during renovation in a chest institute. , 2017, , .		0
549	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) â€“ a multicenter study. Open Forum Infectious Diseases, 2020, 7, S795-S796.	0.9	0
550	Differential Pneumococcal Growth Features in Severe Invasive Disease Manifestations. Microbiology Spectrum, 0, , .	3.0	0